Heat Biologics CEO to Present at the ThinkEquity Conference in New York City
Back to Newsroom
Mentioned in this Article

Heat Biologics CEO to Present at the ThinkEquity Conference in New York City

Thursday, April 18, 2019 5:30 PM
Share this article now
Topic:
Conferences

DURHAM, NC / ACCESSWIRE / April 18, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, announces that Jeff Wolf, Chief Executive Officer, is scheduled to present at the ThinkEquity Conference on Thursday, May 2nd, at 8:00 AM Eastern Time, which is being held at The Mandarin Oriental Hotel in New York City.

Additional information on the conference is available at, https://www.think-equity.com/thinkequity-conference.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform ("TCAP") produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our ComPACT technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®) and with Merck's pembrolizumab (Keytruda®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. For more information, please visit www.heatbio.com.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
[email protected]

SOURCE: Heat Biologics, Inc.

Heat Biologics, Inc.
Exchange:
Ticker:
NASDAQ
HTBX
$0.0000
NaN%
Back to Newsroom
Copyright 2020 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: